What is Nested Therapeutics?
Founded in 2021, Nested Therapeutics operates at the intersection of genomics, proteomics, and computational chemistry. The company is dedicated to the discovery and development of novel, targeted, small-molecule precision medicine therapies. By utilizing advanced AI-driven insights to identify druggable pockets within mutation clusters, the firm aims to unlock therapeutic potential for patients suffering from complex oncological conditions. This platform-centric approach allows the company to systematically target mutations that have historically remained beyond the reach of conventional pharmaceutical interventions, positioning Nested as a high-potential player in the next generation of cancer therapeutics.
How much funding has Nested Therapeutics raised?
Nested Therapeutics has raised a total of $90M across 1 funding round:
Series A
$90M
Series A (2022): $90M with participation from Goldman Sachs, Avidity Partners, and Foresite Capital
Key Investors in Nested Therapeutics
Goldman Sachs
Goldman Sachs is a leading global investment banking and management firm providing comprehensive financial services, including strategic advisory and capital market support for high-growth enterprises.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data to address unmet medical needs.
Avidity Partners
Avidity Partners is a specialized investment firm that focuses on the healthcare sector, providing strategic capital to innovative companies developing breakthrough medical technologies.
What's next for Nested Therapeutics?
With the recent influx of capital, Nested Therapeutics is expected to accelerate its lead programs through preclinical validation and toward initial clinical trials. The strategic focus will likely remain on refining its AI-driven discovery engine to identify new therapeutic targets while simultaneously scaling its internal research and development infrastructure. As the company matures, the focus will shift from platform validation to the execution of clinical development milestones, which will be critical for establishing long-term value in the precision medicine market. The firm's ability to translate computational insights into tangible clinical outcomes will be the primary metric for its future growth and potential for strategic partnerships or further financing rounds.
See full Nested Therapeutics company page
